Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244725 · ClinicalTrials.gov registry record · Phase 2
Odiparcil For The Prevention Of Venous Thromboembolism
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 961
- Enrollment target
NCT00244725 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 961 participants.
The verdict
NCT00244725, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 961 participants
- Enrollment target
Study Summary
Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.
Interventions
- DRUG Warfarin
- DRUG Coumadin
- DRUG Odiparcil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 961 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244725
The ClinicalTrials.gov registry entry for NCT00244725 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 961 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Warfarin is the first listed.
NCT00244725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244725 about?
NCT00244725 is a clinical study titled "Odiparcil For The Prevention Of Venous Thromboembolism". Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.
What is the current status of trial NCT00244725?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 961 participants. The study started on 2005-09. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00244725?
The interventions under investigation include: Warfarin (DRUG), Coumadin (DRUG), Odiparcil (DRUG).
Who is sponsoring clinical trial NCT00244725?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.